Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
SUGAR FREE PILL FOR CANCER PAIN

 

Sugar-free pill Actiq for cancer pain

 

BY OUR PHARMA CORRESPONDENT

13 September,2005: The US Food and Drug Administration (FDA) has granted approvable letter to market a new sugar-free pain pill Actiq (fentanyl citrate), Cephalon Inc announced in a press release.

The sugar-free oral formulation, which is bioequivalent to the currently available product Actiq, will be marketed as a treatment option to cancer patients with breakthrough pain.

Actiq is the first medication approved for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Pain is a primary symptom reported by cancer patients. Of those taking chronic opioid medication for their persistent pain, an estimated 64 to 86 percent experience breakthrough cancer pain. Breakthrough pain is a sudden flare of pain that "breaks through" the relief provided by the pain medication taken around-the-clock to treat underlying persistent pain. The typical episode in cancer patients may peak in as little as three to five minutes, with up to four flares a day. Flares of breakthrough pain are typically severe in intensity and may be excruciating. They often come on suddenly or may be related to a specific activity ("incident pain"). Breakthrough pain can be caused by the cancer itself, treatment, or other cancer-related conditions.

Actiq contains a strong pain-relieving medication (an opioid analgesic) called fentanyl that is used to treat breakthrough cancer pain in patients with malignancies who are taking and who are tolerant to around-the-clock opioid medication for their underlying moderate-to-severe persistent cancer pain. 

Actiq is a single-use medicated lozenge, attached to a handle, which delivers fentanyl as the unit is moved along the inside lining of the cheeks. The most serious adverse effects associated with all opioids are respiratory depression (potentially leading to apnea and respiratory arrest), circulatory depression, hypotension, and shock. All patients should be followed for symptoms of respiratory depression. The most common side effects observed in Actiq clinical trials were tiredness, nausea, vomiting, and dizziness. Frequently, however, these adverse events will cease or decrease in intensity with continued use of Actiq, as the patient is titrated to the proper dose.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company into the discovery, development and marketing of products to treat sleep and neurological disorders, cancer and pain. Cephalon currently employs approximately 2,300 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France and other European offices are located in Guildford, England, and Martinsried, Germany.

The company currently markets four proprietary products in the United States: Provigil (modafinil), Gabitril (tiagabine hydrochloride), Actiq, and Trisenox (arsenic trioxide) injection, and more than 20 products internationally.

BY OUR PHARMA CORRESPONDENT

 

   Pharma Home
LATEST UPDATES

Chinese herbal products could be dangerous: UK 

Knock, knock! It's bird flu at the door

Spider anti-venom to be stocked in UAE hospital 

US may ban animal protein in cattle feed to safeguard against mad cow 

Dr Reddy's nizatidine generic gets FDA nod

Late-onset Pompe disease drug goes on trial

First biologic to treat ulcerative colitis gets US FDA okay

Diverticulitis orally dissolving pill from KV Pharma's  hits the market

Impax delisted from Nasdaq

US FDA okays Lupin's cephalexin

Hepatitis C combo therapy to get priority review in Japan

Lung cancer vaccine trials promising: Introgen

Sugar-free pill Actiq for cancer pain

39 drug firms sued over price rigging in California

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us